Complement activation in vivo in cancer patients receiving C. Parvum immunotherapy

H. Biran, J. L. Moake, R. C. Reed, J. U. Gutterman, E. M. Hersh, E. J. Freireich, G. M. Mavligit

Research output: Contribution to journalArticle

Abstract

Serum complement levels were assayed in 26 patients with disseminated cancer, who received immunotherapy with infusion of C. parvum. Complement activation, indicated by the consumption of C3 or C4 or both, was found in 46% of the patients. Serum samples showed direct correlation between decreased C3 and conversion of C3 proactivator, whereas such conversion did not occur when C4 alone was decreased. It is concluded that the bypass (properdin) pathway was activated in patients in whom C3 consumption was detected, while the classical (C1) pathway was activated in the patients with C4 consumption unaccompanied by C3 decrease. Direct correlation was observed between delayed cutaneous hypersensitivity reactions to recall antigens and the incidence of C. parvum-associated complement activation.

Original languageEnglish (US)
Pages (from-to)493-499
Number of pages7
JournalBritish Journal of Cancer
Volume34
Issue number5
DOIs
StatePublished - 1976
Externally publishedYes

Fingerprint

Complement Activation
Immunotherapy
Neoplasms
Alternative Complement Pathway
Complement Factor B
Delayed Hypersensitivity
Serum
Antigens
Skin
Incidence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Biran, H., Moake, J. L., Reed, R. C., Gutterman, J. U., Hersh, E. M., Freireich, E. J., & Mavligit, G. M. (1976). Complement activation in vivo in cancer patients receiving C. Parvum immunotherapy. British Journal of Cancer, 34(5), 493-499. https://doi.org/10.1038/bjc.1976.215

Complement activation in vivo in cancer patients receiving C. Parvum immunotherapy. / Biran, H.; Moake, J. L.; Reed, R. C.; Gutterman, J. U.; Hersh, E. M.; Freireich, E. J.; Mavligit, G. M.

In: British Journal of Cancer, Vol. 34, No. 5, 1976, p. 493-499.

Research output: Contribution to journalArticle

Biran, H, Moake, JL, Reed, RC, Gutterman, JU, Hersh, EM, Freireich, EJ & Mavligit, GM 1976, 'Complement activation in vivo in cancer patients receiving C. Parvum immunotherapy', British Journal of Cancer, vol. 34, no. 5, pp. 493-499. https://doi.org/10.1038/bjc.1976.215
Biran, H. ; Moake, J. L. ; Reed, R. C. ; Gutterman, J. U. ; Hersh, E. M. ; Freireich, E. J. ; Mavligit, G. M. / Complement activation in vivo in cancer patients receiving C. Parvum immunotherapy. In: British Journal of Cancer. 1976 ; Vol. 34, No. 5. pp. 493-499.
@article{67dbff3eefa145d8905b5d27e1684b7f,
title = "Complement activation in vivo in cancer patients receiving C. Parvum immunotherapy",
abstract = "Serum complement levels were assayed in 26 patients with disseminated cancer, who received immunotherapy with infusion of C. parvum. Complement activation, indicated by the consumption of C3 or C4 or both, was found in 46{\%} of the patients. Serum samples showed direct correlation between decreased C3 and conversion of C3 proactivator, whereas such conversion did not occur when C4 alone was decreased. It is concluded that the bypass (properdin) pathway was activated in patients in whom C3 consumption was detected, while the classical (C1) pathway was activated in the patients with C4 consumption unaccompanied by C3 decrease. Direct correlation was observed between delayed cutaneous hypersensitivity reactions to recall antigens and the incidence of C. parvum-associated complement activation.",
author = "H. Biran and Moake, {J. L.} and Reed, {R. C.} and Gutterman, {J. U.} and Hersh, {E. M.} and Freireich, {E. J.} and Mavligit, {G. M.}",
year = "1976",
doi = "10.1038/bjc.1976.215",
language = "English (US)",
volume = "34",
pages = "493--499",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Complement activation in vivo in cancer patients receiving C. Parvum immunotherapy

AU - Biran, H.

AU - Moake, J. L.

AU - Reed, R. C.

AU - Gutterman, J. U.

AU - Hersh, E. M.

AU - Freireich, E. J.

AU - Mavligit, G. M.

PY - 1976

Y1 - 1976

N2 - Serum complement levels were assayed in 26 patients with disseminated cancer, who received immunotherapy with infusion of C. parvum. Complement activation, indicated by the consumption of C3 or C4 or both, was found in 46% of the patients. Serum samples showed direct correlation between decreased C3 and conversion of C3 proactivator, whereas such conversion did not occur when C4 alone was decreased. It is concluded that the bypass (properdin) pathway was activated in patients in whom C3 consumption was detected, while the classical (C1) pathway was activated in the patients with C4 consumption unaccompanied by C3 decrease. Direct correlation was observed between delayed cutaneous hypersensitivity reactions to recall antigens and the incidence of C. parvum-associated complement activation.

AB - Serum complement levels were assayed in 26 patients with disseminated cancer, who received immunotherapy with infusion of C. parvum. Complement activation, indicated by the consumption of C3 or C4 or both, was found in 46% of the patients. Serum samples showed direct correlation between decreased C3 and conversion of C3 proactivator, whereas such conversion did not occur when C4 alone was decreased. It is concluded that the bypass (properdin) pathway was activated in patients in whom C3 consumption was detected, while the classical (C1) pathway was activated in the patients with C4 consumption unaccompanied by C3 decrease. Direct correlation was observed between delayed cutaneous hypersensitivity reactions to recall antigens and the incidence of C. parvum-associated complement activation.

UR - http://www.scopus.com/inward/record.url?scp=84966160904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966160904&partnerID=8YFLogxK

U2 - 10.1038/bjc.1976.215

DO - 10.1038/bjc.1976.215

M3 - Article

VL - 34

SP - 493

EP - 499

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -